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We isolated Andes virus (formal name: Andes virus [ANDV], a species in the genus Hantavirus), from
serum of an asymptomatic 10-year-old Chilean boy who died 6 days later of hantavirus pulmonary syn-
drome (HPS). The serum was obtained 12 days after his grandmother died from HPS and 2 days before
he became febrile. No hantavirus immunoglobulin (Ig) G or IgM antibodies were detected in the serum
sample. After three blind passages, ANDV antigens were detected in Vero E6 cells by immunofluores-
cence assay and enzyme-linked immunosorbent assay, and ANDV RNA was detected by reverse tran-
scription-polymerase chain reaction. A fragment of the virus genome showed 96.2% nucleotide identity
with that of prototype ANDV. To our knowledge, this is the first isolation of any agent of hemorrhagic fever
with HPS from a human and the first such isolation of hantavirus before symptoms of that syndrome or
HPS began. 
antaviruses are rodent-borne negative-sense RNA viruses
that cause hemorrhagic fever with renal syndrome or
hantavirus pulmonary syndrome (HPS) in humans (1). HPS is
caused by New World hantaviruses that have been identified
since the syndrome was first recognized in the southwestern
United States in 1993 (2). The syndrome is characterized by
four stages: the febrile prodrome, the cardiopulmonary stage,
diuresis, and convalescence. The cardiopulmonary phase,
which typically lasts 2–10 days, can range from a mild illness,
characterized by shortness of breath and need for supplemental
nasal oxygen, to severe cardiopulmonary involvement with
respiratory failure, lactic acidosis, shock, and death (3,4). In
survivors, diuresis occurs abruptly and is usually associated
with rapid clinical improvement. The course and duration of
the convalescent stage are more variable, but most patients
describe persistent fatigue and limited tolerance for exercise
for at least several months.
HPS has been reported in Argentina, Brazil, Canada,
Chile, Panama, Paraguay, Uruguay, and the United States;
mortality rates range from 40% to 50% (1). In Chile, 135 cases
of HPS have been reported through February 9, 2001, with a
48.8% mortality rate (5). Andes virus (formal name: Andes
virus [ANDV], a species in the genus Hantavirus), which is
carried by Oligoryzomys longicaudatus, is responsible for
most HPS cases in Argentina and Chile. In contrast, Sin Nom-
bre virus (formal name: Sin Nombre virus [SNV]), which is
carried by Peromyscus maniculatus, is the primary pathogen in
North America. No evidence has been found to support per-
son-to-person transmission of SNV, but person-to-person
transmission of ANDV has been documented in one large out-
break in Argentina (6) and is suggested by case clustering in
household contacts in Chile (M. Ferres, X. Aguilera, pers.
comm.).
Most patients are seen at the onset of the cardiopulmonary
phase, and information about clinical and laboratory findings,
viremia, and immune responses is most complete for this and
subsequent phases (7,8). Less is known about clinical and lab-
oratory findings, viremia, and immune responses during the
febrile prodrome, although both specific immunoglobulin (Ig)
G and IgM antibodies are almost always present during this
phase (9). In contrast, no information is available on the devel-
opment or time course of viremia or immune responses before
symptoms begin (in the prodromal phase). We describe the
first isolation of hantavirus from a human in the Americas and
the first isolation of hantavirus from a human before onset of
symptoms of HPS or hemorrhagic fever with renal syndrome.
Patients and Methods
Case Descriptions
The index patient was a 54-year-old woman who had head-
ache, myalgias, and abdominal pain on August 26, 1999, fol-
lowed several days later by respiratory symptoms. She went to
the hospital on August 31, where she was diagnosed with
bilateral pneumonia and adult respiratory distress syndrome;
she died on September 1. A serum sample obtained on August
31 was reactive for IgM antibodies. The patient’s 71-year-old
brother had had a febrile illness on August 7, 1999, and was
hospitalized 2 days later with a clinical diagnosis of acute
abdominal pain, pyelonephritis, shock, and bilateral pulmo-
nary infiltrates; he died on August 10. HPS was not suspected,
and no serum or tissue was available for testing when HPS was
diagnosed in the index patient. 
The Ministry of Health initiated a routine evaluation
of household and neighborhood contacts on September 13,
1999. Blood was obtained from 10 asymptomatic  contacts,
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including the 10-year-old grandson of the index patient. On
September 15, the grandson became febrile, and headache and
vomiting developed. Two days later, he (patient 99-7913) was
evaluated as an outpatient. His physical examination showed
fever (38°C) and no respiratory symptoms. His leukocyte
count was 13,000/µL, hematocrit 46.9%, hemoglobin 15.7 g/
dL, and platelet count 125,000/µL. The plasma C reactive pro-
tein was 39 mg/L. Diffuse bilateral interstitial pulmonary infil-
trates were detected on chest radiograms, and the patient was
treated with a macrolide antibiotic for presumed pneumonia.
He returned to the hospital the morning of September 18 with-
out fever, with arterial pressure 110/60 mmHg, tachycardia
(100 beats per minute), and weakness. Pneumonia, obstructive
bronchial syndrome, and dehydration were diagnosed. He was
treated with intravenous penicillin, hydration, and aerosolized
salbutamol. He returned to the hospital again on the evening of
September 18 with respiratory failure and shock and died on
September 19 within hours of arrival. No additional serum or
tissue samples were obtained at the outpatient visit or in the
hospital.
Epidemiologic Studies
Routine epidemiologic evaluation of each confirmed HPS
case in Chile includes rodent trapping around the patient’s
household and evaluation of household and family contacts.
The latter includes a clinical evaluation for history of recent
fever or other symptoms and the administration of a question-
naire to assess risk factors for hantavirus infection. A serum
sample is obtained from household and family contacts by
venipuncture and transported to the Institute of Public Health
in Santiago for determination of hantavirus antibodies. 
Biosafety Procedures
We followed the recommendations of the Centers for Dis-
ease Control and Prevention (CDC) in all aspects of this work
(10). Antibody studies were conducted at biosafety level 2
(BSL-2) facilities, but viral isolation attempts were conducted
at BSL-3 laboratories in the Instituto de Salud Pública labora-
tory in Santiago. 
Detection of Antibodies to SNV in Patient Serum
We detected antibodies from patient serum samples by
enzyme-linked immunosorbent assay (ELISA) with nucleo-
capsid (N) antigens of SNV and Laguna Negra (formal name:
Laguna Negra virus [LNV]) virus. These diagnostic tests were
obtained from CDC in Atlanta, Georgia (11). SNV antigen was
used in the solid phase for detecting IgG antibodies, and LNV
antigen was used in an antigen-capture format for detecting
specific IgM antibodies, as described (11). 
Isolation of ANDV from Patient Serum
Virus was isolated by a conventional method, with three
blind passages in monolayers of Vero E6 cells (12). We grew
Vero E6 cells to confluence in T25 flasks with minimal essen-
tial media containing 10% fetal calf serum and antibiotics, and
then replaced the media with 1.5 mL of fresh media containing
0.5 mL of serum from patient 99-7913. After 1 hour, we added
4.5 mL of fresh media and maintained the cells at 37°C in 5%
CO2 for 26 days, refeeding twice per week (Tissue Culture 1
or TC-1). At 26 days, the cells were treated with trypsin and
split 1:2 into fresh T25 flasks (TC-2). At 24 days postinocula-
tion (dpi), we trypsinized the cells and replated them into fresh
T25 flasks (TC-3). At 14 dpi, we trypsinized the cells and
replated them into fresh T25 flasks (TC-4). At 13 dpi,  we
treated the cells with trypsin and replated them after removing
5 x104 for indirect immunofluorescence assay (IFA) analysis.
IFA
Fifty thousand inoculated Vero E6 cells were washed twice
with phosphate-buffered saline and dried on a microscope
spot-slide for IFA testing. As a control, we used uninoculated
Vero E6 cells that were processed in parallel. The cells were
stained according to Gallo et al. (13), using a 1:1,000 dilution
of rabbit polyclonal anti-Andes N. Cells were considered to be
positive for hantavirus antigen if we observed punctate cyto-
plasmic and Golgi staining in the presence of anti-N antibody
but not in the presence of preimmune rabbit serum or if the
cells had not been injected with a source of ANDV.
Reverse Transcription-Polymerase 
Chain Reaction (RT-PCR)
We conducted nested RT-PCR to detect a portion of the
viral N gene by using generic primers for S segment as
described (14). The coordinates of the primers, designated S1
and S2 (outer primers), were at 2 and 593, whereas the inner
primers S3 and S4 were at coordinates 22 and 359. We deter-
mined that an amplification reaction was positive if we could
visualize a 338-bp band after electrophoresis through agarose,
as described (14). 
Phylogenetic Studies
Nucleotide sequences examined corresponded to positions
22–359 of antigenome-sense sequence of nucleoprotein gene.
Genetic relationships of the Chilean isolate with homologous
sequences of previously characterized hantavirus were
obtained by the maximun parsimony method with the Clustal
W and PHYLIP packages (15). 
Results
The grandson’s death from suspected HPS was reported on
September 21. Serum obtained on September 13, which had
been transported and stored at 4°C, was tested for the presence
of hantavirus antibodies by ELISA. Neither IgG nor IgM anti-
body was detected. Serum was then injected into tissue Vero
E6 cell monolayers to attempt viral isolation (12). 
Virus Isolation
Inoculated and noninoculated Vero E6 cells were cultivated
for several weeks. After three blind passages in new monolay-
ers of Vero E6 cells, the presence of hantaviral antigens wasEmerging Infectious Diseases  •  Vol. 8, No. 7, July 2002 659
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tested by IFA with serum samples from seropositive Chilean
HPS patients. Only the cells derived from the patient serum-
inoculated tissue culture expressed fluorescent inclusion bodies
(Figure 1). Over 90% of the cells became fluorescent. The
specificity of this reaction was further tested by ELISA with
cellular lysates prepared from infected and noninfected cells
and ANDV antibody-positive rabbit sera. The absorbance val-
ues obtained by using lysates of infected cells were higher than
those from noninfected cells (data not shown). To further con-
firm the presence of hantavirus infection in the Vero E6 cells,
we also used nested RT-PCR of the nucleoprotein gene to test
tissue cultures inoculated with patient serum with generic
primers for S segment (14). Only the RNA extract from patient
sera-inoculated cells showed an amplified product with the
expected 338-bp fragment. The amplified product was not
detected in mock-infected cells (data not shown).
The amplified DNA product was sequenced and compared
with the sequence of prototype strains (Figure 2). The Chilean
hantavirus isolate, designated CHI-7913, showed 96.2%
nucleotide identity with the prototypical ANDV sequence, but
only 81.1%–82.5% identity with SNV from the southwestern
United States (14). 
Discussion
Previous human isolates of hantaviruses have been
reported only for Old World viral species, and no isolates have
been described from patients who were asymptomatic. Since
previous attempts at other laboratories had been unsuccessful,
we attempted isolation before the onset of symptoms, and our
first attempt to do so was successful. Our results document the
presence of infectious hantaviral virions in a serum specimen
obtained from a seronegative 10-year-old child 2 days before
his symptoms began and 6 days before his death from HPS.
We excluded the possibility of laboratory contamination since
no hantavirus was or had been in use in our laboratory nor
were we making other attempts to isolate hantavirus.
Based on the partial S segment sequence we obtained, the
isolate CHI-7913 is a geographic variant of ANDV. Compari-
son of CHI-7913 virus N gene sequence with the correspond-
ing sequences of representative New World hantaviruses
showed the highest degree of identity with that of ANDV. 
Isolation of hantaviruses from rodents and humans has
been difficult, and isolation from humans has been particularly
so. Many apparent human isolates were obtained in laborato-
ries that were actively cultivating a number of hantavirus
strains at the time of the isolation. Thus, several earlier human
isolates have proven difficult to confirm as independent iso-
lates after they were subjected to genetic comparison with pre-
viously obtained rodent isolates (25). Other human isolates
that have been reported more recently have not been subjected
to similar scrutiny. In 19 attempts over more than a decade,
Juto et al. reported one successful attempt at isolation of Puu-
mala virus (formal name: Puumala virus [PUUV]) from phy-
tohemagglutinin-stimulated human leukocytes (26). In a report
of isolation of Hantaan virus (formal name: Hantaan virus
[HTNV]) from peritoneal exudate cells collected from a
patient with severe hemorrhagic fever with renal syndrome on
the 10th day of illness, Gu et al. noted that human isolation of
HTNV is easier from blood collected during the first 4 days of
illness than from blood collected after day 6 (27). Examining
these and other human isolates of PUUV and HTNV by
sequence analysis will be valuable in confirming their inde-
pendent origin, much as we have been able to do with CH-
7913.
We suspect that development of neutralizing antibody
early in symptomatic illness may be the primary factor leading
to difficulty in isolation of hantavirus from blood in humans
after illness has begun. Bharadwaj et al. recently reported
detecting neutralizing antibody in all sera obtained at the day
of hospital admission in patients with SNV-associated HPS
(9). Although most hospital admissions occurred at the onset
of the cardiopulmonary stage, neutralizing antibody was also
detected in a limited number of sera available 1 or 2 days
before hospital admission, during the prodromal phase. The
recent report that viral RNA detected by RT-PCR inevitably
declines early in hospitalization (7,28) is also consistent with
the hypothesis that virus is present but that neutralizing anti-
body and other immune responses are already reducing the
titer and infectiousness of hantaviruses by the cardiopulmo-
nary stage of illness. That stage is when most patients come to
medical attention. 
We were able to isolate hantavirus from serum obtained 2
days before symptoms began and before the production of
detectable levels of IgG or IgM antibodies. This finding sug-
gests that a viremic phase may precede symptoms and that the
onset of symptoms in the prodromal stage may be associated
with humoral and cellular immune responses rather than vire-
mia. In contrast to HPS in North America, where case clusters
are uncommon, approximately one third of HPS cases in Chile
have occurred in clusters involving members of the same
household or other close contacts (M Ferres, X Aguilera, pers.
comm.). Of these, most have involved case clusters with
symptom onset separated by 2–4 weeks rather than case clus-
Figure 1. Immunofluorescence assay (IFA) of Vero E6 cells infected
with Chilean hantavirus CHI-7913 isolate. A, IFA with seropositive
human sera from a Chilean HPS patient; arrow shows infected Vero E6
cells expressing hantavirus antigens. B, IFA with seronegative human
sera from uninfected control; arrow shows the negative IFA of Vero E6
cells infected with the CHI-7913 isolate.RESEARCH
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ters with closely related dates of symptom onset. As such,
Chile may pose a unique opportunity to prospectively follow
close contacts of index patients to determine whether viremia
routinely precedes symptoms as well as to identify and per-
haps treat some persons early in the course of symptomatic
hantavirus illness.
Acknowledgments
The authors are grateful to O. Roos for excellent technical assis-
tance with tissue culture; B. Hjelle for providing Vero E6 cells, train-
ing on the handling of hantaviruses in the laboratory, and helpful
discussions; and P. Padula for providing cellular lysates from infected
and uninfected cells and Andes virus antibody-positive rabbit sera
used in tests. 
Financial support was provided in part by U.S. Public Health Ser-
vice grants AI45452 (HG, JM, and GJM) and TW01133 (GJM). 
Dr. Galeno works in the hantavirus laboratory at the Public
Health Institute of Chile. He is conducting research on immune
responses (neutralizing antibodies) of infected patients. 
References
1. Schmaljohn C, Hjelle B. Hantavirus: a global disease problem. Emerg
Infect Dis 1997;3:95–104.
2. Nichol ST, Spiropoulou CF, Morzunov S, Rollin PE, Ksiazek TG, Fel-
mann H, et al. Genetic identification of a hantavirus associated with an
outbreak of acute respiratory illness. Science 1994;262:832–6. 
3. Duchin JS, Koster F, Peters CJ, Simpson GL, Tempest B, Zaki SR, et al.
Hantavirus pulmonary syndrome: a clinical description of 17 patients
with a newly recognized disease. N Engl J Med 1994;330:949–55.
4. Hallin G, Simpson S, Crowell R, James DS, Koster FT, Mertz GJ, et al.
Cardiopulmonary manifestations of hantavirus pulmonary syndrome. Crit
Care Med 1996;24:252–8.
5. Chilean Ministry of Health. Epidemiologic report of Hantavirus in Chile.
Santiago, Chile: the Ministry; 2001. 
6. Padula PJ, Edelstein A, Miguel SD, Lopez NM, Rossi CM, Rabinovich
RD. Hantavirus pulmonary syndrome outbreak in Argentina: molecular
evidence for person-to-person transmission of Andes virus. Virology
1998;241:323–30.
7. Terajima M, Hendershot JD, Kariwa H, Koster FT, Hjelle B, Goade D, et
al. High levels of viremia in patients with the hantavirus pulmonary syn-
drome. J Infect Dis 1999;180:2030–4.
8. Mertz GJ, Hjelle BL, Williams TM, Koster FT. Host responses in the
Hantavirus cardiopulmonary syndrome. In: Saluzzo JF, Dodet B, editors.
Factors in the emergence and control of rodent-borne viral diseases. Paris:
Elsevier; 1999. p. 133–7.
9. Bharadwaj M, Nofchissy R, Goade D, Koster F, Hjelle B. Humoral
immune responses in the hantavirus cardiopulmonary syndrome. J Infect
Dis 2000;182:43–8.
10. Centers for Disease Control and Prevention and National Institutes of
Health. Biosafety in microbiological and biomedical laboratory (BMBL).
4th edition. Washington: U.S. Government Printing Office; 1999. 
11. Rossi C, Ksiazek T. Virus detection and identification with serological
tests. 2. Enzyme-linked immunosorbent assay (ELISA). In: Lee H W,
Calisher C, Schmaljohn C, editors. Manual of hemorrhagic fever with
renal syndrome and hantavirus pulmonary syndrome. Seoul: WHO Col-
laborating Centre for Virus Reference and Research (Hantavirus); 1999.
p. 87–91.
12. Lee HW. Virus isolation. In: Lee HW, Calisher C, Schmaljohn C, editors.
Manual of hemorrhagic fever with renal syndrome and hantavirus pulmo-
nary syndrome. Seoul: WHO Collaborating Centre for Virus Reference
and Research (Hantavirus); 1999. p. 74–9.
13. Gallo D, Penning LM, Hanson CV. Detection and differentiation of anti-
bodies to human T-cell lymphotropic virus types I and II by immunofluo-
rescence method. J Clin Microbiol 1991;29:2345–7.
14. Lopez N, Padula P, Rossi C, Miguel S, Edelstein A, Ramirez E, et al.
Genetic characterization and phylogeny of Andes virus and variants from
Argentina and Chile. Virus Res 1997;50:77–84.
15. Kuhner MK, Felsenstein J. A simulation comparison of phylogeny algo-
rithms under equal and unequal evolutionary rates. Mol Biol Evol
1994;11:459–68.
16. Ravkov EV, Rollin PE, Ksiazek TG, Peters CJ, Nichol ST. Genetic and
serologic analysis of Black Creek Canal virus and its association with
human disease and Sigmodon hispidus infection. Virology 1995;210:482–
9. 
17. Morsunov S, Feldmann H, Spiropoulou CF, Semenova VA, Rollin PE,
Ksiazek TG, et al. A newly recognized virus associated with a fatal case
of hantavirus pulmonary syndrome in Louisiana. J Virol 1995;69:1980–3.
18. Hjelle B, Krolikowski J, Torrez-Martinez N, Chavez-Giles F, Vanner C,
Laposata E. Phylogenetically distinct hantavirus implicated in a case of
hantavirus pulmonary syndrome in the northeastern United States. J Med
Virol 1995;46:21–7.
Figure 2. Maximum-parsimony tree analysis comparing S nucleotide
sequence of CHI-7913 virus with homologous sequences of previously
characterized hantaviruses. Nucleotide sequences examined corre-
spond to positions 22–359 of antigenome-sense sequence of nucleo-
protein (N) gene. Sequences were analyzed by the maximun parsi-
mony method with the Clustal W and PHYLIP packages (15). The mini-
mal length trees shown were supported as the majority rule consensus
tree in 500 replicates. The bootstrap replicates supporting each node
are indicated. References and GenBank accession numbers for the
sequences used in S segment comparisons are BCC (16) L39949; BAY
(17) L36929; NY strain RI-1 (18), U09488; SN strain cc107 (19),
L33683; SN strain nmh10 (20), L25784; PH strain PH-1 (21), and
M34011; Puumala  strains Sotkamo (22), X61035; Seoul (SEO) strain
sr-11 (23), and M34881; Hantaan (HTN) strain 76-118 (24), M14626;
Andes strain AH-1 (14), AF004660; ESQ H-1/96 (14), AF005948; CH
H-1/96 (14), AF 005947; AND Nort (strain unpublished) AF325966; and
Andes strain 23 (AF291702).Emerging Infectious Diseases  •  Vol. 8, No. 7, July 2002 661
RESEARCH
19. Schmaljohn AL, Li D, Negley DL, Bressler DS, Turrell MJ, Korch GW,
et al. Isolation and initial characterization of a new-found hantavirus from
California. Virology 1995;206:963–72.
20. Spriropoulou CF, Morzunov S, Feldmann H, Sanchez A, Peters CJ,
Nichol ST. Genome structure and variability of a virus causing hantavirus
pulmonary syndrome. Virology 1994;200:715–23.
21. Parrington MA, Kang YC. Nucleotide sequence analysis of the S
genomic segment of Prospect Hill virus: comparison with the prototype
hantavirus. Virology 1990;175:167–75. 
22. Vapalahti O, Kallio-Kokko H, Salonen EM, Brummer-Korvenkontio M,
Vaheri A. Cloning and sequencing of Puumala virus Sotkamo strain S and
M RNA segments: evidence for strain variation in hantavirus and expres-
sion of the nucleocapsid protein. J Gen Virol 1992;73:829–38.
23. Arikawa J, Lapenotiere HF, Iacono-Connors L, Wang M, Schmaljohn CS.
Coding properties of the S and M genome segments of Sapporo rat virus:
comparison to other causative agents of hemorrhagic fever with renal
syndrome. Virology 1990;176:114–25.
24. Schmaljohn CS, Jennings AL, Hay J, Dalrymple JM. Coding strategy of
the S genome segment of Hantaan virus. Virology 1986;155:633–43.
25. Xiao SY, Leduc JW, Chu YK, Schmaljohn CS. Phylogenetic analyses of
virus isolates in the genus Hantavirus, family Bunyaviridae. Virology
1994;198:205–17.
26. Juto P, Elgh F, Ahlm C, Alexeyev OA, Edlund K, Lundkvist A, et al. The
first human isolate of Puumala virus in Scandinavia as cultured from phy-
tohemagglutinin stimulated leucocytes. J Med Virol 1997;53:150–6.
27. Gu XS, Song ZB, Jin ZW, Meng GR, Zhang CA, Yan DY, et al. Isolation
of a strain of Hantaan virus from peritoneal exudate cells of a patient with
hemorrhagic fever with renal syndrome. Chin Med J 1990;103:455–9.
28. Hjelle B, Spiropoulou CF, Torrez-Martinez N, Morzunov S, Peters CJ,
Nichol ST. Detection of Muerto Canyon virus RNA in peripheral blood
mononuclear cells from patients with hantavirus pulmonary syndrome. J
Infect Dis 1994;170:1013–7.
Address for correspondence: Eugenio Ramirez, Public Health Institute of
Chile, Av. Marathon 1000, Santiago, Chile; fax: 562-3507573; e-mail:
eramirez@ispch.cl
For more on hantavirus
Search past issues of EID at www.cdc.gov/eid